Celestica Inc.
NYSE:CLSHardware, Equipment & Parts
-$6.28 today
- Market cap
- $30.69B
- Beta
- 1.48
- P/E (TTM)
- 44.8
- EPS (TTM)
- $8.35
Volume 2.61M
Average 2.23M
CLS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Celestica Inc.NYSE: CLS
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development grows, but more slowly than its trailing trend
Q3 FY2026 research & development of $51.2M rose 40.7% year over year, behind the +51.6% change in trailing-twelve-month research & development. Sequentially, it rose 10.6% from the prior quarter. Over 3 fiscal years it compounded at +36.7% a year.
Context
- Research & development amounted to 1.0% of revenue in FY2025, up 0.1 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +40.7% toward the trailing-twelve-month pace of +51.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 118.2M USD
- Year-over-year change
- +51.5%
- 4-year CAGR
- +32.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 118.2M | +51.5% |
| FY2024 | 2024-12-31 | 78M | +28.1% |
| FY2023 | 2023-12-31 | 60.9M | +31.5% |
| FY2022 | 2022-12-31 | 46.3M | +20.6% |
| FY2021 | 2021-12-31 | 38.4M | — |
Research & Development vs competitors
How CLS compares with its peers on the latest reported figures
- CLS's LTM Sep 2026 research & development of $168.9M is the highest of the 6 companies compared; the peer median is $0.
- Its year-over-year change of +51.6% is the highest of 3, against a peer median of +10.8%.
- Research & development amounts to 0.9% of revenue for CLS, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $168.9M | +51.6% | +36.7% | 0.9% | |
| LTM Oct 2026 | $32.99M | +6.1% | +7.7% | 0.2% | |
| LTM Aug 2026 | $30M | +15.4% | -4.1% | 0.1% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jul 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CLS) | $0 | +10.8% | +1.8% | 0.0% | |
Competitors are the stored peer set for CLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.63B | 7.25B | 7.96B | 9.65B | 12.39B |
| Cost of Revenue | 5.15B | 6.6B | 7.21B | 8.61B | 10.9B |
| Gross Profit | 487M | 649.7M | 754.1M | 1.03B | 1.49B |
| Gross Margin | 8.6% | 9.0% | 9.5% | 10.7% | 12.1% |
| Research & Development | 38.4M | 46.3M | 60.9M | 78M | 118.2M |
| Selling, General & Admin | 245.1M | 267.3M | 303.2M | 293.5M | 259.9M |
| Operating Expenses | 319.3M | 360.4M | 415.8M | 434.4M | 423.7M |
| Depreciation & Amortization | 126.3M | 115.9M | 130.8M | 151.9M | 175.7M |
| EBITDA | 293.72M | 406.7M | 515.7M | 736.2M | 1.21B |
| EBITDA Margin | 5.2% | 5.6% | 6.5% | 7.6% | 9.8% |
| Operating Income | 167.7M | 289.3M | 338.3M | 599.3M | 1.07B |
| Operating Margin | 3.0% | 4.0% | 4.2% | 6.2% | 8.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 31.42M | 51.7M | 78.9M | 52.1M | 53.52M |
| Other Income / Expenses | (31.7M) | (50.2M) | (32.3M) | (67.1M) | (87.2M) |
| Income Before Tax | 136M | 239.1M | 306M | 532.2M | 983.2M |
| Pre-Tax Margin | 2.4% | 3.3% | 3.8% | 5.5% | 7.9% |
| Income Tax Expense | 32.1M | 59M | 61.6M | 104.2M | 150.7M |
| Net Income | 103.9M | 180.1M | 244.4M | 428M | 832.5M |
| Net Margin | 1.8% | 2.5% | 3.1% | 4.4% | 6.7% |
| EPS (Basic) | 0.82 | 1.46 | 2.04 | 3.62 | 7.35 |
| EPS (Diluted) | 0.82 | 1.46 | 2.03 | 3.61 | 7.29 |
| Weighted Avg Shares | 126.7M | 123.5M | 120.1M | 118.1M | 115.3M |
| Weighted Avg Shares (Diluted) | 126.7M | 123.6M | 120.3M | 118.7M | 116.2M |
Celestica Inc.
NYSE:CLS
Intrinsic Alpha fair value
Locked
Current Price
$243.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.